August has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Humana, Merck and Mayo Clinic named new executives. There were also layoffs at organizations including MaineHealth, Cellares and Sharp HealthCare. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.

In this episode, we’re joined by Amanda Shafton, practicing CNM and national director of midwifery at Ob Hospitalist Group. We discuss the benefits of physician/midwifery collaboration and how midwives can improve maternal health outcomes. The post MedCity FemFwd: How Midwives Can Support the Maternal Health Crisis appeared first on MedCity News.

Health tech companies made several major funding announcements in August. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in August appeared first on MedCity News.

Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations. The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare Blood Disorder appeared first on MedCity News.

If AI is not one of the CEO’s top two or three priorities, the organization will produce pilots and slide decks while better-mobilized peers pull ahead and the institution’s ability to fulfill its mission erodes The post AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation appeared first on MedCity News.

A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care. The post Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up appeared first on MedCity News.

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on MedCity News.

When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance.  The post The Missing Piece in Lowering the Cost of Care: Predictability appeared first on MedCity News.

More than a dozen health systems are warning patients of a phishing campaign impersonating Epic’s MyChart portal with fake Medicare rewards and faux login pages. Experts say the scam exposes a deeper problem: patients can’t be expected to spot increasingly polished fakes, so the responsibility falls on providers to communicate in ways that build trust. The post Epic MyChart Phishing Scam Hits Health Systems: What Providers Should Do appeared first on MedCity News.

Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential. The post FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy appeared first on MedCity News.

Chronic wounds demand clinicians willing to act outside of their defined role, not because the system incentivizes it, but because without it, the wound will not heal. The post The Silent Epidemic: Why Diabetic Foot Ulcers Have Been Overlooked for Three Decades appeared first on MedCity News.

We are on the cusp of an age of anticipatory medicine, an explosion in our ability to read the body’s signals and catch the killers before they do their damage. The post Reading the Body’s Signals: AI’s Ultimate Healthcare Opportunity appeared first on MedCity News.

AstraZeneca and Amgen drug Tezspire met the goals of a Phase 3 test in eosinophilic esophagitis (EoE), a chronic disorder whose only approved biologic therapy is Sanofi’s Dupixent. An approval for Tezspire in EoE would be its third indication, bolstering sales of the blockbuster product. The post AstraZeneca, Amgen Drug Moves Closer to Competing With Dupixent in a New Indication appeared first on MedCity News.

Datavant launched a new provider exchange platform, which replaces fax-based record requests with a digital workflow. It aims to give care teams real-time visibility into request status while easing the administrative burden on clinical staff. The post Datavant’s New Platform Could Cut Record Retrieval Time from Days to Hours appeared first on MedCity News.

It’s time we reignite treatment development for sepsis and other immune-mediated conditions that strike when patients are most vulnerable.  The post Precision Medicine Transformed Oncology —It’s Time to Do the Same for Sepsis appeared first on MedCity News.